These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4842314)

  • 1. Proceedings: Reversible contraceptive action of testosterone in males.
    Reddy PR
    J Reprod Fertil; 1974 May; 38(1):232. PubMed ID: 4842314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC; Jouannet P; Marson J; Soumah A
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of norethandrolone and testosterone as a contraceptive agent for men.
    Brenner PF; Bernstein GS; Roy S; Jecht EW; Mishell DR
    Contraception; 1975 Feb; 11(2):193-207. PubMed ID: 1112088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on the use of testosterone oenanthate as a male contraceptive agent.
    Mauss J; Börsch G; Richter E; Bormacher K
    Contraception; 1974 Sep; 10(3):281-9. PubMed ID: 4374338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.
    Bremner WJ; Bagatell CJ; Steiner RA
    J Clin Endocrinol Metab; 1991 Sep; 73(3):465-9. PubMed ID: 1874925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is high dosage testosterone an effective male contraceptive agent?
    Matsumoto AM
    Fertil Steril; 1988 Aug; 50(2):324-8. PubMed ID: 3396702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target sites for suppressing fertility in the male.
    Prasad MR; Rajalakshmi M
    Adv Sex Horm Res; 1976; 2():263-87. PubMed ID: 797248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
    Knuth UA; Yeung CH; Nieschlag E
    Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies with cyproterone acetate for male contraception.
    Roy S; Chatterjee S
    J Steroid Biochem; 1979 Jul; 11(1B):675-80. PubMed ID: 491632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antispermatogenic effects of tolnidamine in langur (Presbytis entellus).
    Lohiya NK; Ansari AS; Scorza Barcellona P
    Contraception; 1991 May; 43(5):485-96. PubMed ID: 1914461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrimethamine: an approach to the development of a male contraceptive.
    Cosentino MJ; Pakyz RE; Fried J
    Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1431-5. PubMed ID: 2304908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Male contraception and vasectomy.
    Emperaire JC; Audebert A; Mattei A
    Contracept Fertil Sex (Paris); 1977; 5(4):335-42. PubMed ID: 12260083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial with levo-norgestrel and testosterone oenanthate for male fertility control.
    Føgh M; Corker CS; McLean H; Hunter WM; Petersen IB; Philip J; Schou G; Skakkebaek NE
    Acta Endocrinol (Copenh); 1980 Oct; 95(2):251-7. PubMed ID: 6776755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH immunization and male infertility: immunocontraception potential.
    Awoniyi CA
    Adv Contracept Deliv Syst; 1994; 10(3-4):279-90. PubMed ID: 12287842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.